MYH3

Across TCGA pan-cancer cohorts, MYH3 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated MYH3 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MYH3 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated MYH3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

UCEC, BRCA, and HNSC are the cancer types where MYH3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.983	0.605	<.001	34	view →
BRCA	OS	Median	II,III,IV	0.583	0.913	<.001	20	view →
HNSC	OS	Median	All	0.215	0.613	.001	15	view →
LGG	OS	Median	All	0.221	0.889	<.001	6	view →
SARC	OS	Median	All	0.108	0.827	<.001	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
PRAD	DFS	Median	All	0.617	0.886	.038	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	3	view →
BLCA	OS	Median	III,IV	0.799	0.643	.047	1	view →
SKCM	OS	Median	III,IV	0.899	0.777	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

MYH3–UCEC (DFS)

Open the UCEC breakdown →